ChangAn Unveils Vast Ocean Plan Global Expansion Milestones Following Official Launch of First International NEV Factory in Rayong, Thailand
RAYONG, Thailand, May 20, 2025 /PRNewswire/ -- ChangAn Automobile ("ChangAn" or "the Company"), an intelligent low-carbon mobility technology company, recently officially commenced production at its first international NEV manufacturing base in Rayong, Thailand, coinciding with both the roll-off of its 28.59-millionth vehicle, and the celebration of the 50th anniversary of diplomatic ties between China and Thailand, marking a truly major milestone. The factory launch is a landmark event of ChangAn's Vast Ocean Plan for global expansion that represents a shift from brand internationalisation to the export of full industries.
Mr. Zhu Huarong, Chairman of ChangAn Automobile, shared: "Our aim is to build this factory as a global benchmark. We will continue to focus on long-term growth, and mutually beneficial, low-carbon, localised operations. To lead sustainable mobility and benefit human life is ChangAn's mission, and despite the huge challenges currently posed by anti-globalisation, we are fully committed to our Vast Ocean Plan."
ChangAn's Vast Ocean Plan drives global expansion across five regions, advancing its goal of becoming a world-class automobile brand. Over three years, the Company filed over 14,000 patents, with 70% for inventions, averaging 19 per workday, maintaining top R&D rankings. ChangAn fosters global talent focusing on professionalism, youth, internationalisation, and market orientation. Its industrial footprint includes 20 planned factories, with nine KD plants and one full vehicle plant operational. Marketing includes 22 brand launches across Southeast Asia, Europe, Latin America, the Middle East and Africa, with over 9,000 outlets. ESG investments exceed 30 million yuan annually, supporting public welfare worldwide.
ChangAn's Vast Ocean Plan has accelerated the Company's global expansion since its 2023 launch. With five major international regions established, ChangAn set overseas sales records in 2024. As the plan enters a new phase in 2025, the Company is sharing high-quality products and services worldwide at the speed of China. In Southeast Asia and Oceania, ChangAn has cultivated key right-hand-drive markets. Construction of the Rayong factory in Thailand began in November 2023, and mass production started in May 2025. In the region, the DEEPAL S05 and extended-range EV debuted at the 2025 Bangkok International Motor Show. The factory marks a shift from product exports to full-industry exports. In Latin America, ChangAn hosted a brand conference on July 23, 2024, accelerating the rollout of high-value products to meet diverse local needs. After 30 years in the Middle East and Africa, a brand launch in September 2024 introduced six new energy models. Plans include local subsidiaries, joint ventures, and expanded services. In Europe, where ChangAn established its Turin Design Center in 2001, a brand launch in Germany on March 21, 2025, marked renewed commitment to sustainable mobility through localised R&D and the "In Europe, For Europe" strategy.
ChangAn will pursue its "four ones" development goals and advance its global strategy, elevating five major international markets to the same strategic level as China. The Company aims to grow its global market capacity from 30 million to 50 million and accelerate localisation in these regions. ChangAn plans to expand production with 11 KD projects in countries such as Kazakhstan and Egypt, reaching 500,000 vehicles in international capacity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
9 hours ago
- Korea Herald
KEENON Debuts First Bipedal Humanoid Service Robot at WAIC, Showcasing Role-Specific Embodied AI Solutions
SHANGHAI, July 26, 2025 /PRNewswire/ -- The world premiere of KEENON Robotics' bipedal humanoid service robot, XMAN-F1, takes center stage at the World Artificial Intelligence Conference (WAIC) 2025 in Shanghai from July 26 to 29, where the pioneer in embodied intelligence showcases its latest innovations on the global stage for breakthrough AI advancements. Transforming its showground into an Embodied Service Experience Hub, KEENON immerses visitors in three interactive scenarios—medical station, lounge bar, and performance space—highlighting how embodied AI solution is actively reshaping future lifestyles and industrial ecosystems. At the event, XMAN-F1 emerges as the core interactive demonstration, showcasing human-like mobility and precision in service tasks across diverse scenarios. From preparing popcorn to mixing personalized chilled beverages such as Sprite or Coke with adjustable ice levels, the robot demonstrates remarkable environmental adaptability and task execution. Scheduled stage appearances feature XMAN-F1 autonomously delivering digital presentations and product demos, powered by multimodal interaction and large language model technologies. Its fluid movements and naturalistic gestures establish it as the primary focus of attention, with visitors gathering to witness its engagement live. The demonstration spotlights further multi-robot collaboration in specialized environments. At the medical station, the humanoid XMAN-F1 partners with logistics robot M104 to create a closed-loop smart healthcare solution. The bar area features a highlight collaboration with Johnnie Walker Blue Label—the world's leading premium whisky—where robotic bartenders work alongside delivery robot T10 to craft and serve bespoke beverages. The seamless multi-robot integration not only enhances operational efficiency but signals the dawn of robotic system interoperability, moving far beyond single-task automation. According to IDC's latest report, KEENON leads the commercial service robot sector with 22.7% of global shipments and holds a definitive 40.4% share in food delivery robotics. At WAIC 2025, the company reinforces its market leadership while presenting its ecosystem-based strategy for cross-scenario embodied intelligence solutions. Looking ahead, KEENON will continue driving innovation in embodied intelligence, combining cutting-edge R&D and global partnerships to unlock the full potential of 'Robotics+' applications worldwide.
Korea Herald
12 hours ago
- Korea Herald
CGTN: How China's economy remains vibrant despite U.S. tariff war
BEIJING, July 26, 2025 /PRNewswire/ -- With Chinese Vice Premier He Lifeng to hold economic and trade talks with the United States in Sweden later this month, the strength and resilience of the Chinese economy is in the limelight once again. This round of talks, mutually agreed upon by both nations, is not only a diplomatic engagement but also a testament to China's enduring economic vitality in a complex international environment. Recent statistics underscore the robustness of China's economy. In the first half of 2025, the GDP grew by an impressive 5.3 percent year on year, surpassing market expectations despite global headwinds. This number reflects more than temporary growth; it exhibits the structural resilience and adaptability of an economy that continues to evolve and upgrade. Domestic demand emerged as the cornerstone of growth, contributing 68.8 percent to GDP expansion in this period. Initiatives such as large-scale equipment upgrades and consumer goods trade-in programs have effectively stimulated spending, cushioning China's economy from external shocks. In the first five months of 2025 alone, China's consumer goods trade-in program generated 1.1 trillion yuan ($153.1 billion) in sales, surpassing the figure for entire 2024. Boosted by the program, China's retail sales of consumer goods grew 5 percent year on year in the past six months – 0.4 percentage point faster than the growth recorded in the first quarter. While external uncertainties have introduced some pressure, China's trade diversification and the steady output of high-tech manufacturing and service industries have provided strong support to the economy. Though China's trade with some Western countries declined, its trade with Belt and Road partners, ASEAN countries, the European Union, and African nations saw respective increases of 4.7 percent, 9.6 percent, 3.5 percent, and 14.4 percent in the first half of 2025. This expansion of trade relationships has helped China reduce its reliance on any one market, lessening the impact of some Western economies' protectionist policies. China's resilience reverberates beyond its borders. As a crucial driver of global growth, China's steady economic performance boosts international market confidence and provides a stabilizing influence amid global uncertainties. Through continued focus on quality growth and opening up, China offers the international community a reliable engine for shared prosperity. A recent report from the U.S.-China Business Council indicates that 82 percent of American companies operating in China turned a profit in 2024. Though many cited the uncertainties in China-U.S. relations and tariffs as their main worry, the Chinese market continues to be crucial for them. Trade tensions pose obstacles, yet they have not crippled the resilience in the Chinese economy. The upcoming Beijing-Washington talks in Sweden demonstrate China's willingness to tackle differences via negotiations. While obstacles remain, China's ability to sustain growth, adapt to changing global landscapes, and engage constructively with international partners signals a future of shared opportunities and mutual advancement.
Korea Herald
18 hours ago
- Korea Herald
Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 26, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the " Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy and safety. Analysis results of the 90 patients enrolled in the Phase II Stage showed that: The hair growth assessment (" HGA") indicators from investigators of 0.5% BID group and 1.0% BID group both experienced significant improvement from placebo group, with a significant therapeutic effect. The results showed that after the treatment of 24 weeks, compared to the placebo group, the HGA indicator of the 0.5% BID group displayed statistically significant results (P=0.000); compared to the placebo group, the HGA indicator of the 1.0% BID group displayed statistically significant results (P=0.013). The analysis results were reviewed by the Independent Data Monitoring Committee (IDMC), and its primary recommendation was that the Phase III Stage clinical trial should continue based on the current safety and efficacy data, with no modifications to treatment group or sample size.
